Discovery, Development and Application of Drugs Targeting BCL-2 Pro-survival Proteins in Cancer

Overview

Journal Biochem Soc Trans

Specialty Biochemistry

Date 2021 Sep 13

PMID 34515749

Citations 3

Authors

Erinna F Lee

W Douglas Fairlie

Affiliations

Soon will be listed here.

Abstract

The discovery of a new class of small molecule compounds that target the BCL-2 family of anti-apoptotic proteins is one of the great success stories of basic science leading to translational outcomes in the last 30 years. The eponymous BCL-2 protein was identified over 30 years ago due to its association with cancer. However, it was the unveiling of the biochemistry and structural biology behind it and its close relatives' mechanism(s)-of-action that provided the inspiration for what are now known as 'BH3-mimetics', the first clinically approved drugs designed to specifically inhibit protein-protein interactions. Herein, we chart the history of how these drugs were discovered, their evolution and application in cancer treatment.

Citing Articles

Integrative Investigation of Flavonoids Targeting YBX1 Protein-Protein Interaction Network in Breast Cancer: From Computational Analysis to Experimental Validation.

Sreelekshmi P, Pooja S, Vidya N, Sinosh S, Thejaswini V Mol Biotechnol. 2024; .

PMID: 39565541 DOI: 10.1007/s12033-024-01311-6.

A1 is induced by pathogen ligands to limit myeloid cell death and NLRP3 inflammasome activation.

Speir M, Tye H, Gottschalk T, Simpson D, Djajawi T, Deo P EMBO Rep. 2023; 24(11):e56865.

PMID: 37846472 PMC: 10626451. DOI: 10.15252/embr.202356865.

Differential membrane binding of α/β-peptide foldamers: implications for cellular delivery and mitochondrial targeting.

Lee T, Checco J, Malcolm T, Eller C, Raines R, Gellman S Aust J Chem. 2023; 76(8):482-492.

PMID: 37780415 PMC: 10540276. DOI: 10.1071/ch23063.

References

Letai A, Bassik M, Walensky L, Sorcinelli M, Weiler S, Korsmeyer S . Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell. 2002; 2(3):183-92. DOI: 10.1016/s1535-6108(02)00127-7. View

Mallick D, Soderquist R, Bates D, Eastman A . Confounding off-target effects of BH3 mimetics at commonly used concentrations: MIM1, UMI-77, and A-1210477. Cell Death Dis. 2019; 10(3):185. PMC: 6385300. DOI: 10.1038/s41419-019-1426-3. View

Khan S, Zhang X, Lv D, Zhang Q, He Y, Zhang P . A selective BCL-X PROTAC degrader achieves safe and potent antitumor activity. Nat Med. 2019; 25(12):1938-1947. PMC: 6898785. DOI: 10.1038/s41591-019-0668-z. View

Young A, Law A, Castillo L, Chong S, Cullen H, Koehler M . MCL-1 inhibition provides a new way to suppress breast cancer metastasis and increase sensitivity to dasatinib. Breast Cancer Res. 2016; 18(1):125. PMC: 5146841. DOI: 10.1186/s13058-016-0781-6. View

Koehler B, Jassowicz A, Scherr A, Lorenz S, Radhakrishnan P, Kautz N . Pan-Bcl-2 inhibitor Obatoclax is a potent late stage autophagy inhibitor in colorectal cancer cells independent of canonical autophagy signaling. BMC Cancer. 2015; 15:919. PMC: 4653869. DOI: 10.1186/s12885-015-1929-y. View

Long J, Liu L, Nikolovska-Coleska Z, Shangary S, Yi H, Wang S . Optimization and validation of mitochondria-based functional assay as a useful tool to identify BH3-like molecules selectively targeting anti-apoptotic Bcl-2 proteins. BMC Biotechnol. 2013; 13:45. PMC: 3717276. DOI: 10.1186/1472-6750-13-45. View

Phillips D, Xiao Y, Lam L, Litvinovich E, Roberts-Rapp L, Souers A . Loss in MCL-1 function sensitizes non-Hodgkin's lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199). Blood Cancer J. 2015; 5:e368. PMC: 4670945. DOI: 10.1038/bcj.2015.88. View

He Y, Koch R, Budamagunta V, Zhang P, Zhang X, Khan S . DT2216-a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas. J Hematol Oncol. 2020; 13(1):95. PMC: 7364785. DOI: 10.1186/s13045-020-00928-9. View

Koehler B, Scherr A, Lorenz S, Elssner C, Kautz N, Welte S . Pan-Bcl-2 inhibitor obatoclax delays cell cycle progression and blocks migration of colorectal cancer cells. PLoS One. 2014; 9(9):e106571. PMC: 4156353. DOI: 10.1371/journal.pone.0106571. View

10.

Leverson J, Zhang H, Chen J, Tahir S, Phillips D, Xue J . Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax). Cell Death Dis. 2015; 6:e1590. PMC: 4669759. DOI: 10.1038/cddis.2014.561. View

11.

Chen L, Willis S, Wei A, Smith B, Fletcher J, Hinds M . Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell. 2005; 17(3):393-403. DOI: 10.1016/j.molcel.2004.12.030. View

12.

Czabotar P, Westphal D, Dewson G, Ma S, Hockings C, Fairlie W . Bax crystal structures reveal how BH3 domains activate Bax and nucleate its oligomerization to induce apoptosis. Cell. 2013; 152(3):519-31. DOI: 10.1016/j.cell.2012.12.031. View

13.

Oltersdorf T, Elmore S, Shoemaker A, Armstrong R, Augeri D, Belli B . An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature. 2005; 435(7042):677-81. DOI: 10.1038/nature03579. View

14.

Kluck R, Bossy-Wetzel E, Green D, Newmeyer D . The release of cytochrome c from mitochondria: a primary site for Bcl-2 regulation of apoptosis. Science. 1997; 275(5303):1132-6. DOI: 10.1126/science.275.5303.1132. View

15.

Zou H, Henzel W, Liu X, Lutschg A, Wang X . Apaf-1, a human protein homologous to C. elegans CED-4, participates in cytochrome c-dependent activation of caspase-3. Cell. 1997; 90(3):405-13. DOI: 10.1016/s0092-8674(00)80501-2. View

16.

Yi H, Qiu M, Yuan L, Luo Q, Pan W, Zhou S . Bcl-2/Bcl-xl inhibitor APG-1252-M1 is a promising therapeutic strategy for gastric carcinoma. Cancer Med. 2020; 9(12):4197-4206. PMC: 7300393. DOI: 10.1002/cam4.3090. View

17.

Wang L, Doherty G, Judd A, Tao Z, Hansen T, Frey R . Discovery of A-1331852, a First-in-Class, Potent, and Orally-Bioavailable BCL-X Inhibitor. ACS Med Chem Lett. 2020; 11(10):1829-1836. PMC: 7549103. DOI: 10.1021/acsmedchemlett.9b00568. View

18.

Brady R, Vom A, Roy M, Toovey N, Smith B, Moss R . De-novo designed library of benzoylureas as inhibitors of BCL-XL: synthesis, structural and biochemical characterization. J Med Chem. 2014; 57(4):1323-43. DOI: 10.1021/jm401948b. View

19.

Kotschy A, Szlavik Z, Murray J, Davidson J, Maragno A, Le Toumelin-Braizat G . The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models. Nature. 2016; 538(7626):477-482. DOI: 10.1038/nature19830. View

20.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View